PulseSight Therapeutics is a clinical-stage biotech company developing disruptive, non-viral gene therapies dedicated to ophthalmology, with a current focus on age-related macular degeneration (AMD) including late-stage dry AMD/Geographic atrophy (GA) and wet AMD.
Latest news
January 22, 2026
PulseSight Completes Enrollment in Gene Therapy Trial
January 22, 2026
A New Attack on Blindness: PulseSight Completes Key Safety Trial for Novel Dry AMD Gene Therapy
January 22, 2026
Dosing completed in the Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy (GA)